SevenBridge Financial Group LLC Increases Stake in Becton, Dickinson and Company (NYSE:BDX)

SevenBridge Financial Group LLC raised its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,627 shares of the medical instruments supplier’s stock after acquiring an additional 310 shares during the quarter. SevenBridge Financial Group LLC’s holdings in Becton, Dickinson and Company were worth $2,963,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. WR Wealth Planners LLC raised its stake in shares of Becton, Dickinson and Company by 1.4% in the second quarter. WR Wealth Planners LLC now owns 2,978 shares of the medical instruments supplier’s stock worth $696,000 after purchasing an additional 42 shares during the last quarter. Clear Creek Financial Management LLC raised its position in Becton, Dickinson and Company by 5.1% during the 2nd quarter. Clear Creek Financial Management LLC now owns 900 shares of the medical instruments supplier’s stock worth $210,000 after buying an additional 44 shares during the last quarter. Sound Income Strategies LLC lifted its stake in Becton, Dickinson and Company by 35.8% during the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 44 shares during the period. Central Pacific Bank Trust Division boosted its holdings in shares of Becton, Dickinson and Company by 22.5% in the 3rd quarter. Central Pacific Bank Trust Division now owns 245 shares of the medical instruments supplier’s stock valued at $59,000 after acquiring an additional 45 shares during the last quarter. Finally, Tompkins Financial Corp increased its stake in shares of Becton, Dickinson and Company by 44.2% in the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 46 shares during the period. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Down 0.6 %

Becton, Dickinson and Company stock opened at $224.00 on Friday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.17 and a quick ratio of 0.74. The stock has a market capitalization of $64.74 billion, a PE ratio of 37.71, a price-to-earnings-growth ratio of 1.68 and a beta of 0.43. The business has a 50 day simple moving average of $235.15 and a 200-day simple moving average of $234.54. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $249.89.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, topping the consensus estimate of $3.77 by $0.04. The company had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The firm’s revenue was up 6.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.42 EPS. On average, analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 31st. Investors of record on Monday, December 9th will be paid a $1.04 dividend. The ex-dividend date is Monday, December 9th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 dividend on an annualized basis and a yield of 1.86%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 63.97%.

Analyst Ratings Changes

BDX has been the topic of several recent research reports. Raymond James lowered their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. Evercore ISI lifted their price target on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Finally, Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $255.00 to $275.00 in a research note on Tuesday, October 1st. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Buy” and a consensus target price of $283.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.